Latest news with #RichardLipscombe
The Age
4 days ago
- Health
- The Age
New Proteomics blood test unlocks better oesophageal cancer detection
Newly published results from ASX-listed diagnostics trailblazer Proteomics International Laboratories have unveiled stunning new clinical findings for its simple PromarkerEso oesophageal cancer blood test, opening the way for the innovative blood test to be commercially released. The test's accuracy was demonstrated in a 259-person study across three patient groups in Australia and the United States. The results were posted overnight in the peer-reviewed journal Proteomes, providing a major academic rubber stamp for the technology. The new findings showed that the test could detect a whopping 91.4 out of 100 patients with the heartburn-related cancer and correctly identify 98.9 per cent of people without it, offering a powerful, non-invasive alternative to costly and uncomfortable endoscopies. Based on the results, PromarkerEso outperforms many tests currently used for screening other types of cancers. For context, the widely used Prostate-Specific Antigen blood test used to diagnose prostate cancer has an Area Under Curve (AUC) measurement of just 0.68, while PromarkerEso hit an exceptional AUC of 0.98. An AUC greater than 0.7 is considered to offer acceptable discrimination, while above 0.9 is considered outstanding. 'The published results represent a major advancement in our mission to transform the lives of people living with chronic acid reflux.' Proteomics International Laboratories managing director Dr Richard Lipscombe Described by the company as a landmark moment in non-invasive diagnostics, PromarkerEso uses a standard blood draw to flag at-risk patients using a traffic light system that grades patients at low, moderate and high risk of developing the cancer. The results are delivered with near-laboratory precision and without the need for specialist procedures. Proteomics says the breakthrough could transform early detection of one of the world's deadliest and most overlooked cancers, which often goes undiagnosed until it's too late. Specifically, the disease targeted by the test is oesophageal adenocarcinoma, which is often caused by chronic heartburn, or acid reflux, and affects up to 20 per cent of people in Western populations. Despite the high incidence, current detection methods rely on invasive endoscopy procedures that are uncomfortable and expensive. In the US, an endoscopy costs about US$2750 (A$4200) per procedure. Even with this rigorous scrutiny, up to 90 per cent of cases go undetected.
Sydney Morning Herald
4 days ago
- Health
- Sydney Morning Herald
New Proteomics blood test unlocks better oesophageal cancer detection
Newly published results from ASX-listed diagnostics trailblazer Proteomics International Laboratories have unveiled stunning new clinical findings for its simple PromarkerEso oesophageal cancer blood test, opening the way for the innovative blood test to be commercially released. The test's accuracy was demonstrated in a 259-person study across three patient groups in Australia and the United States. The results were posted overnight in the peer-reviewed journal Proteomes, providing a major academic rubber stamp for the technology. The new findings showed that the test could detect a whopping 91.4 out of 100 patients with the heartburn-related cancer and correctly identify 98.9 per cent of people without it, offering a powerful, non-invasive alternative to costly and uncomfortable endoscopies. Based on the results, PromarkerEso outperforms many tests currently used for screening other types of cancers. For context, the widely used Prostate-Specific Antigen blood test used to diagnose prostate cancer has an Area Under Curve (AUC) measurement of just 0.68, while PromarkerEso hit an exceptional AUC of 0.98. An AUC greater than 0.7 is considered to offer acceptable discrimination, while above 0.9 is considered outstanding. 'The published results represent a major advancement in our mission to transform the lives of people living with chronic acid reflux.' Proteomics International Laboratories managing director Dr Richard Lipscombe Described by the company as a landmark moment in non-invasive diagnostics, PromarkerEso uses a standard blood draw to flag at-risk patients using a traffic light system that grades patients at low, moderate and high risk of developing the cancer. The results are delivered with near-laboratory precision and without the need for specialist procedures. Proteomics says the breakthrough could transform early detection of one of the world's deadliest and most overlooked cancers, which often goes undiagnosed until it's too late. Specifically, the disease targeted by the test is oesophageal adenocarcinoma, which is often caused by chronic heartburn, or acid reflux, and affects up to 20 per cent of people in Western populations. Despite the high incidence, current detection methods rely on invasive endoscopy procedures that are uncomfortable and expensive. In the US, an endoscopy costs about US$2750 (A$4200) per procedure. Even with this rigorous scrutiny, up to 90 per cent of cases go undetected.
Sydney Morning Herald
26-05-2025
- Health
- Sydney Morning Herald
Proteomics on fast track to deliver simple endometriosis blood test
ASX-listed diagnostics innovator Proteomics International Laboratories plans to start a commercial roll-out of its groundbreaking, simple 'traffic light' diagnostic blood test for endometriosis within months, in the process revolutionising healthcare for the disease. The company says its latest trial of its PromarkerEndo test has put it on a fast track to deliver the first clinically viable, real-world, non-invasive diagnostic test for a disease affecting one in nine women and girls and costing the Australian economy nearly $10 billion. Over the weekend, Proteomics released the results of its latest trial, involving 704 blood plasma samples, to leading medical specialists and researchers at the prestigious World Congress on Endometriosis in Sydney. The trial used a diagnostic test consolidated from earlier prototype models to compare cases of endometriosis with general population controls and symptomatic patients. Proteomics said the trial delivered stunning accuracy in diagnosing cases across all stages of the debilitating disease. 'This is a major step forward in making non-invasive endometriosis diagnosis a reality.' Proteomics International Laboratories managing director Dr Richard Lipscombe In a sector where a diagnosis has traditionally taken an average of seven years and involved a painful and invasive laparoscopy and tissue biopsy, this simple blood test is poised to flip the script entirely. For the first time, doctors may soon swap the scalpel for a simple fingerprick blood test, with PromarkerEndo positioned to become the frontline tool in detecting endometriosis in symptomatic patients. PromarkerEndo uses a universal 'traffic light' risk score - low, moderate or high - to indicate a patient's likelihood of having endometriosis. In validation trials, the test clocked an overall accuracy score of 0.92 and reached up to 98 per cent sensitivity in severe cases. It has a robust stage one accuracy performance of 89 per cent in early-stage disease, which is often the hardest to detect. Proteomics International Laboratories managing director Dr Richard Lipscombe said: 'This is a major step forward in making non-invasive endometriosis diagnosis a reality. The advances support our commercialisation strategy and reinforce the potential for PromarkerEndo to become a standard part of the clinical diagnostic pathway.'
The Age
26-05-2025
- Health
- The Age
Proteomics on fast track to deliver simple endometriosis blood test
ASX-listed diagnostics innovator Proteomics International Laboratories plans to start a commercial roll-out of its groundbreaking, simple 'traffic light' diagnostic blood test for endometriosis within months, in the process revolutionising healthcare for the disease. The company says its latest trial of its PromarkerEndo test has put it on a fast track to deliver the first clinically viable, real-world, non-invasive diagnostic test for a disease affecting one in nine women and girls and costing the Australian economy nearly $10 billion. Over the weekend, Proteomics released the results of its latest trial, involving 704 blood plasma samples, to leading medical specialists and researchers at the prestigious World Congress on Endometriosis in Sydney. The trial used a diagnostic test consolidated from earlier prototype models to compare cases of endometriosis with general population controls and symptomatic patients. Proteomics said the trial delivered stunning accuracy in diagnosing cases across all stages of the debilitating disease. 'This is a major step forward in making non-invasive endometriosis diagnosis a reality.' Proteomics International Laboratories managing director Dr Richard Lipscombe In a sector where a diagnosis has traditionally taken an average of seven years and involved a painful and invasive laparoscopy and tissue biopsy, this simple blood test is poised to flip the script entirely. For the first time, doctors may soon swap the scalpel for a simple fingerprick blood test, with PromarkerEndo positioned to become the frontline tool in detecting endometriosis in symptomatic patients. PromarkerEndo uses a universal 'traffic light' risk score - low, moderate or high - to indicate a patient's likelihood of having endometriosis. In validation trials, the test clocked an overall accuracy score of 0.92 and reached up to 98 per cent sensitivity in severe cases. It has a robust stage one accuracy performance of 89 per cent in early-stage disease, which is often the hardest to detect. Proteomics International Laboratories managing director Dr Richard Lipscombe said: 'This is a major step forward in making non-invasive endometriosis diagnosis a reality. The advances support our commercialisation strategy and reinforce the potential for PromarkerEndo to become a standard part of the clinical diagnostic pathway.'
Sydney Morning Herald
22-04-2025
- Business
- Sydney Morning Herald
Proteomics banks $4.5M to fast-track novel diagnostic test launches
Medical innovator Proteomics International Laboratories is charging into selling mode after locking away $4.5 million from institutional and sophisticated investors to fast-track the roll-out of its novel Promarker diagnostic tests across Australia and the United States. The Perth-based biotech is known for its pioneering work in predictive diagnostics through the large-scale study of proteins. Its new funds will propel the launch of three first-in-class blood tests, the PromarkerD for diabetic kidney disease, PromarkerEso for oesophageal cancer and PromarkerEndo for endometriosis. The placement was priced at 37 cents per share with one free-attaching option for every two shares and was snapped up at a nearly 18 per cent discount on the company's recent trading price. Directors and key management also jumped on board, pledging a further $500,000 subject to shareholder approval. A $1M share purchase plan is also on the table, giving existing investors a shot at the action. 'The funds will drive the US and Australian launch of our suite of diagnostic tests.' Proteomics International Laboratories managing director Dr Richard Lipscombe The first-of-its-kind PromarkerD predictive blood test can detect the likely risk of a diabetic patient developing chronic kidney disease up to four years before symptoms appear. It is now being rolled out in the US. PromarkerEso tackles a notoriously difficult-to-detect cancer by picking up those patients at risk because of chronic acid reflux. Trials have shown the test has a remarkable 94 per cent accuracy in diagnosing oesophageal cancer in patients. The test is now ready for public sale. Proteomics is also set to launch PromarkerEndo for early endometriosis detection between June and September this year when patents are locked in across all the major markets. The test offers a simple blood test for a condition that is currently chronically underserviced and can take an average of seven years to diagnose.
